Record Nr.	UNINA9910300201603321
Titolo	Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development: A Focus on Early Phase Clinical Studies / / edited by Andrew J. Krentz, Lutz Heinemann, Marcus Hompesch
Pubbl/distr/stampa	London:,: Springer London:,: Imprint: Springer,, 2015
ISBN	1-4471-4920-3
Edizione	[1st ed. 2015.]
Descrizione fisica	1 online resource (316 p.)
Disciplina	610 615 615.19 616 616.39 616.46 616462
Soggetti	Medicine Internal medicine Diabetes Metabolic diseases Pharmacology Pharmaceutical technology Medicine/Public Health, general Internal Medicine Metabolic Diseases Pharmacology/Toxicology Pharmaceutical Sciences/Technology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references at the end of each chapters and index.
Nota di contenuto	Review of physiology/pathophysiology 2. Methods for assessing insulin action in humans 3. Assessment of insulin secretion 4.

1.

Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for the measurement of metabolic flux -- 6. Measuring food intake in clinical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9. Assessment of cardiovascular safety of new diabetes drugs.

Sommario/riassunto

This book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development. Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties.